PolyPeptide Group

Update in progress

PPGN.SW (Swiss)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

PolyPeptide Group AG is a contract development and manufacturing organization that produces synthetic peptides for active pharmaceutical ingredients and intermediates used in therapies. They offer services and products globally, including GLP-1–related metabolic therapies, generic peptides, and peptides for cosmetics, animal health, and medical devices, plus development and analytical services. Clients include academia, pharma, and biotech. Founded 1952, based in Baar, Switzerland; subsidiary of Draupnir Holding B.V.

Company score

Sentiment: 0.24; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.18; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.14; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.08; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.16; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive